Company profile: Xyphos
1.1 - Company Overview
Company description
- Provider of CAR-T cell therapy platforms for treating relapsed hematological malignancies and solid tumors. Offers ACCEL, which uses engineered ligands to precisely control activity and targeting of universal convertibleCAR-T with tumor-specific antibodies, and ConvertibleCAR, a technology modifying NKG2D to enable flexible multi-antigen targeting and enhanced immune cell activation.
Products and services
- ACCEL™: Architects a modular platform using engineered ligands to precisely control activity and targeting of universal convertibleCAR-T cells via any tumor-specific full antibody, enabling adaptable cancer cell therapy
- ConvertibleCAR™: Engineers a custom-engineered NKG2D receptor modification to produce flexible CAR-T therapies that target multiple tumor antigens and enhance immune cell activation to destroy tumor cells
- ConvertibleCAR-T: Delivers a universal CAR-T cell retargetable via any tumor-specific full antibody, enabling precise activity control to address relapsed hematological malignancies and solid tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Xyphos
OncoPep
HQ: United States
Website
- Description: Provider of investigational multi-peptide therapeutic cancer vaccines and adoptive T cell therapies, including PVX-410 for patients with triple negative breast cancer (TNBC) and asymptomatic multiple myeloma (MM)/smoldering multiple myeloma (SMM); MTAA-420 for multiple myeloma; and second-generation vaccines PVX-024/PVX-510 to enhance the first iteration of OncoPep's vaccine and expand to additional HLA subtypes, such as HLA-A24.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoPep company profile →
Oncolytics Biotech
HQ: Canada
Website
- Description: Provider of oncolytic virus therapeutics for a broad range of cancers, developing Pelareorep, a nonpathogenic oncolytic virus that selectively replicates in cancer cells to generate immune responses, enhance oncology treatments, and extend patient survival.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncolytics Biotech company profile →
Cidara Therapeutics
HQ: United States
Website
- Description: Provider of drug-Fc conjugate therapeutics built on the Cloudbreak platform, which couples targeted small molecules and peptides to a human antibody fragment (Fc) to inhibit disease targets and engage the immune system; includes CD388, a Phase 2 DFC for preventing seasonal influenza A and B, and CBO421, an IND-enabling oncology DFC targeting CD73 to enhance anti-tumor immunity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cidara Therapeutics company profile →
Pheast
HQ: United States
Website
- Description: Provider of checkpoint therapies to harness the innate immune system, including PHST001, an anti-CD24 antibody that blocks a key macrophage ‘don’t eat me’ signal on cancer cells to induce an anti-cancer immune response, and a proprietary discovery platform that uncovers tumor-specific ‘don’t eat me’ signals to create novel macrophage-targeted immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pheast company profile →
Alligator Bioscience
HQ: Sweden
Website
- Description: Provider of antibody-based immunotherapies for cancer, including next-generation CD40 agonists and bispecific CD40-targeting antibodies, developed using its FIND® (Fragment INduced Diversity) protein optimization technology, and discovering and developing drug candidates up to phase IIa clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alligator Bioscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Xyphos
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Xyphos
2.2 - Growth funds investing in similar companies to Xyphos
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Xyphos
4.2 - Public trading comparable groups for Xyphos
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →